Medlander Medical

Nanjing Medlander Medical Technology Joint-stock Co., Ltd., stock code: 688273.SH (hereinafter referred to as Medlander, English name: Medlander), was established on January 16, 2013, and is committed to becoming a leader in the field of pelvic floor diagnosis and treatment and pelvic floor rehabilitation in China. With the mission of "creating the ultimate health experience" and adhering to the corporate values of innovation, sharing, positivity, and candor, Medlander continuously innovates in the field of pelvic floor rehabilitation, integrates internet fundamentals with pelvic floor diagnosis and treatment technology, and enhances the efficiency of pelvic floor diagnosis and treatment and the medical experience through multiple core patented technologies and big data algorithms. Since its inception, Medlander has developed rapidly over the past 10 years, from its establishment as an independent venture in 2013, to officially entering the obstetrics and gynecology market in 2014, to being recognized as a "High-Tech Enterprise" in July 2015, to entering the international market in 2017, to receiving the Silver Award at the Geneva International Invention Exhibition in Switzerland for its rehabilitation robotic arm in 2018 and being selected as one of Nanjing's first batch of Gazelle Enterprises, to establishing its wholly-owned subsidiary Nanjing Jialan Health Management Co., Ltd. and being approved as the Jiangsu Province Pelvic Floor Rehabilitation Engineering Technology Research Center in 2019, to obtaining the TUV SUD CE certificate and ISO 13485 quality management system certification in 2020, with the group founder Yang Ruijia being selected as a "Science and Technology Innovation and Entrepreneurship Talent" by the Ministry of Science and Technology, and the company being recognized as one of the second batch of "Little Giant" enterprises specializing in new and distinctive technologies by the Ministry of Industry and Information Technology. In June 2021, it was selected as a Nanjing Cultivated Unicorn Enterprise, and in November of the same year, it was approved to establish the Jiangsu Province Postdoctoral Innovation Practice Base. On August 11, 2022, the company was successfully listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange. Currently, the company has become a leading brand in the domestic pelvic floor rehabilitation diagnosis and treatment field, and is actively expanding technological innovation and product development in adjacent areas of pelvic floor health. It now has product lines for medical, non-medical, rehabilitation, and home use, with nearly 500 employees in the group. In the future, Medlander will continue to expand globally, actively explore the international market, and strive to grow into a "leading medical health company focused on women's health and beauty" within 10 years.